Cardiac complications of systemic drugs used in dermatology
DOI:
https://doi.org/10.18203/issn.2455-4529.IntJResDermatol20241730Keywords:
Adverse effects, Drugs, CardiotoxicityAbstract
Within the realm of dermatology, the use of systemic drugs carries implications beyond skin health, often intersecting with cardiovascular outcomes. From antihistamines to biologics, medications prescribed for dermatological conditions may pose varying degrees of risk to the heart. Understanding these potential cardiac side effects is paramount in the comprehensive management of dermatologic patients. This journal article delves into the intricate relationship between systemic dermatologic drugs and cardiovascular health, elucidating the mechanisms underlying cardiotoxicity, identifying patient-specific risk factors, and offering insights into optimizing therapeutic regimens while safeguarding cardiac well-being. Through this exploration, we aim to equip dermatologists with the knowledge necessary for delivering safe and effective care, ensuring the holistic health of their patients.
Metrics
References
Mladěnka P, Applová L, Patočka J, Costa VM, Remiao F, Pourová J, et al. TOX-OER and CARDIOTOX Hradec Králové Researchers and Collaborators. Comprehensive review of cardiovascular toxicity of drugs and related agents. Med Res Rev. 2018;38(4):1332-403.
Güler E, Babur Güler G, Yavuz C, Kızılırmak F. An unknown side effect of isotretinoin: pericardial effusion with atrial tachycardia. Anatol J Cardiol. 2015;15(2):168-9.
Zito PM, Mazzoni T. Acitretin. In: StatPearls. Treasure Island (FL): StatPearls Publishing. Available at: https://www.ncbi.nlm.nih.gov/books /NBK519571/. Accessed on 25 September 2022.
DeAngelo S, Mann KI, Abdulbasit M, Ahnert A, Sundlöf DW. A case report: rapid progression of coronary atherosclerosis in a patient taking Targretin (Bexarotene). Cardio-Oncology. 2020;6:31.
Liu Q, Van Bortle K, Zhang Y, Zhao MT, Zhang JZ, Geller BS, et al. Disruption of mesoderm formation during cardiac differentiation due to developmental exposure to 13-cis-retinoic acid. Sci Rep. 2018;8(1):12960.
Zhang S, Bai YY, Luo LM, Xiao WK, Wu HM, Ye P. Association between serum homocysteine and arterial stiffness in elderly: A community-based study. J Geriatr Cardiol. 2014;11:32-8.
Bălănescu AR, Bojincă VC, Bojincă M, Donisan T, Bălănescu SM. Cardiovascular effects of methotrexate in immune-mediated inflammatory diseases. Exp Ther Med. 2019;17(2):1024-9.
Brown G, Boldt C, Webb JG, Halperin L. Azathioprine-induced multisystem organ failure and cardiogenic shock. Pharmacotherapy. 1997;17:815-8.
Dogan P, Grbovic E, Inci S, Bayraktar F, Cagli K. Azathioprine-induced atrial fibrillation. Intractable Rare Dis Res. 2015;4(4):207-9.
Allison AC, Eugui EM. Preferential suppression of lymphocyte proliferation by mycophenolic acid and predicted long-term effects of mycophenolate mofetil in transplantation. Transplant Proc. 1994;26:3205-10.
Mbaebie N, Shaw P. Chaos in an Attempt to Appease- A Case of Mycophenolate Induced Supraventricular Tachycardia. J Clin Stud Med Case Rep. 2018;5:055.
Braun-Dullaeus RC, Feussner M, Walker G, Hopmann H, Kraemer HJ, Grimminger F, et al. Cyclosporine-induced Coronary Artery Constriction-Dissociation between Thromboxane Release and Coronary Vasospasm. J Heart Lung Transplant. 1999;18(4):328-35.
Ding B, Price RL, Borg TK, Weinberg EO, Halloran PF, Lorell BH. Pressure Overload Induced Severe Hypertrophy in Mice Treated with Cyclosporine, an Inhibitor of Calcineurin. Circ Res. 1999;84:729-34.
Sanghi P, Ahmad M. A case of atrial fibrillation from cyclosporine toxicity. Indian Pacing Electrophysiol J. 2004;4(1):40-2.
Floyd JD, Nguyen DT, Lobins RL, Bashir Q, Doll DC, Perry MC. Cardiotoxicity of cancer therapy. J Clin Oncol. 2005;23(30):7685-96.
Okuyan H, Altın C. Heart failure induced by itraconazole. Indian J Pharmacol. 2013;45(5):524-5.
Ahmad SR, Singer SJ, Leissa BG. Congestive heart failure associated with itraconazole. Lancet 2001;357:1766-7.
Fung SL, Chau CH, Yew WW. Cardiovascular adverse effects during itraconazole therapy. Eur Res J. 2008;32(1):240.
Okamoto J, Fukunami M, Kioka H. Frequent premature ventricular contractions induced by itraconazole. Circ J. 2007;71:1323-5.
Sharkey PK, Rinaldi MG, Dunn JF, Hardin TC, Fetchick RJ, Graybill JR. High dose itraconazole in the treatment of severe mycoses. Antimicrob Agents Chemother. 1991;35:707-13.
Nelson MR, Smith D, Erskine D, Gazzard BG. Ventricular fibrillation secondary to itraconazole induced hypokalaemia. J Infect. 1993;26:348.
Tholakanahalli VN, Potti A, Hanley JF, Merliss AD. Fluconazole-induced torsade de pointes. Ann Pharmacother. 2001;35(4):432-4.
Aris P, Wei Y, Mohamadzadeh M, Xia X. Griseofulvin: An Updated Overview of Old and Current Knowledge. Molecules. 2022;27(20):7034.
Mok NS, Lo YK, Tsui PT, Lam CW. Ketoconazole induced torsades de pointes without concomitant use of QT interval-prolonging drug. J Cardiovasc Electrophysiol. 2005;16(12):1375-7.
Sanches BF, Nunes P, Almeida H, Rebelo M. Atrioventricular block related to liposomal amphotericin B. BMJ Case Rep. 2014;2014:bcr2013202688.
Ray WA, Murray KT, Meredith S, Narasimhulu SS, Hall K, Stein CM. Oral erythromycin and the risk of sudden death from cardiac causes. N Engl J Med. 2004;351(11):1089-96.
Jayaweera DT. Minimising the dosage-limiting toxicities of foscarnet induction therapy. Drug Saf. 1997;16(4):258-66.
Olasińska-Wiśniewska A, Olasiński J, Grajek S. Cardiovascular safety of antihistamines. Postepy Dermatol Alergol. 2014;31(3):182-6.
Kim JH, Cha HR, Ha EK, Kwak JH, Kim H, Shin J, et al. Association between First-Generation Antihistamine Use in Children and Cardiac Arrhythmia and Ischemic Heart Disease: A Case-Crossover Study. Pharmaceuticals. 2023;16(8):1073.
Gagnon LR, Sadasivan C, Yogasundaram H, Oudit GY. Review of Hydroxychloroquine Cardiotoxicity: Lessons From the COVID-19 Pandemic. Curr Heart Fail Rep. 2022;19(6):458-66.
Fram G, Wang DD, Malette K, Villablanca P, Kang G, So K, et al. Cardiac Complications Attributed to Hydroxychloroquine: A Systematic Review of the Literature Pre-COVID-19. Curr Cardiol Rev. 2021;17(3):319-27.
Buttgereit F, Scheffold A. Rapid glucocorticoid effects on immune cells. Steroids. 2002;67:529-34.
Pitzalis C, Pipitone N, Perretti M. Regulation of leukocyte-endothelial interactions by glucocorticoids. Ann N Y Acad Sci. 2002;966:108–18.
Hafezi-Moghadam A, Simoncini T, Yang E, Limbourg FP, Plumier JC, Rebsamen MC, et al. Acute cardiovascular protective effects of corticosteroids are mediated by non-transcriptional activation of endothelial nitric oxide synthase. Nat Med. 2002;8:473-9.
Sholter DE, Armstrong PW. Adverse effects of corticosteroids on the cardiovascular system. Can J Cardiol. 2000;16(4):505-11.
Pujades-Rodriguez M, Morgan AW, Cubbon RM, Wu J. Dose-dependent oral glucocorticoid cardiovascular risks in people with immune-mediated inflammatory diseases: a population-based cohort study. PLoS medicine. 2020;17(12):e1003432.
Souverein PC, Berard A, Van Staa TP, Cooper C, Egberts ACG, Leufkens HGM, et al. Use of oral glucocorticoids and risk of cardiovascular and cerebrovascular disease in a population based case-control study. Heart. 2004;90:859-65.
Jain R, Bali H, Sharma VK, Kumar B. Cardiovascular effects of corticosteroid pulse therapy: A prospective controlled study on pemphigus patients. Int J Dermatol. 2005;44:285-8.
Akikusa JD, Feldman BM, Gross GJ, Silverman ED, Schneider R. Sinus bradycardia after intravenous pulse methylprednisolone. Pediatrics. 2007;119:e778-82.
Dashore S, Pande S, Borkar M, Pande A. Late onset bradycardia: An unusual Side-Effect of high dose dexamethasone pulse therapy in patients of pemphigus vulgaris: A case series of five patients. Indian J Drugs Dermatol. 2015;1:23-6.
Weber MA, Schiffrin EL, White WB, Mann S, Lindholm LH, Kenerson JG, et al. Clinical practice guidelines for the management of hypertension in the community: a statement by the American Society of Hypertension and the International Society of Hypertension. J Clin Hypertens (Greenwich). 2014;16:14-26.
Dlova NC, Jacobs T, Singh S. Pericardial, pleural effusion and anasarca: A rare complication of low-dose oral minoxidil for hair loss. JAAD Case Rep. 2022;28:94-6.
Patil VB, Lunge SB, Doshi BR. Cardiac side effect of rituximab. Indian J Drugs Dermatol. 2020;6:49-52.
Verma SK. Updated cardiac concerns with rituximab use: A growing challenge. Indian Heart J. 2016;68 Suppl 2:S246-8.
Rajagopalan M, Vasani R. Rituximab in the treatment of skin diseases. Indian J Drugs Dermatol. 2017;3(2):105.
Iribarren C, Rahmaoui A, Long AA, Szefler SJ, Bradley MS, Carrigan G, et al. Cardiovascular and cerebrovascular events among patients receiving omalizumab: Results from EXCELS, a prospective cohort study in moderate to severe asthma. J Allergy Clin Immunol. 2017;139(5):1489-1495.e5.
Narukonda S, Vinod NR, Joshi M. A Case of Pulmonary Vein Thrombosis Associated With Treatment of Omalizumab. J Investig Med High Impact Case Rep. 2017;5(3):2324709617724176.
Aguiar-Ricardo I, Nunes-Ferreira A, Roda Â, Bras-Rosario L. Omalizumab induced Takotsubo syndrome: case report. Eur Heart J Case Rep. 2019;3(1):yty155.
Mann DL. Targeted anticytokine therapy and the failing heart. Am J Cardiol. 2005;95:9C-16C.
Senel S, Cobankara V, Taskoylu O, Karasu U, Karapinar H, Erdis E, et al. The safety and efficacy of etanercept on cardiac functions and lipid profile in patients with active rheumatoid arthritis. J Investig Med. 2012;60(1):62-5.
Khan MA, Dormand H, Neyses L, Mamas MA. Heart Failure with Etanercept Therapy: A Case Report. J Clin Exp Cardiol. 2013;4:236.
Martini, S, Masood, F, Chaus, A. Bone fixer or heart breaker: new onset heart failure in the setting of etanercept therapy. J Am Coll Cardiol. 2020;75 (11_Suppl_1):2588.
Mansitó López C, Torres Laboy P, Ortiz Bou M, Quintero Noriega A, Cintron Rivera V. Fatal New-Onset Congestive Heart Failure Related to Adalimumab Use in a Patient with Relapsing Hidradenitis Suppurativa: A Case Report. Am J Case Rep. 2021;22:e929148.
Kavanaugh A, Keystone EC. The safety of biologic agents in early rheumatoid arthritis: Clin Exp Rheumatol. 2003;21(5 Suppl. 31);S203-8.
Chung ES, Packer M, Lo KH, Fasanmade AA, Willerson JT, et al. Randomized, double-blind placebo-controlled pilot trial of infliximab, a chimeric monoclonal antibody to tumor necrosis factor-alpha, in patients with moderate-to-severe heart failure: Results of the anti-TNF Therapy Against Congestive Heart Failure (ATTACH) trial. Circulation. 2003;107(25):3133-40.
Fukuhara M, Matsumura K, Ohmori S, Yanai T, Tsubota Y, Abe I, et al. Effects of interferon on circadian changes in blood pressure and heart rate variability in patients with chronic hepatitis. Am J Hypertension. 1999;12(5):519-23.
Nishio K, Arase T, Tada H, Tachibana H. Interferon related pericarditis: Review. World J Cardiol. 2017;9(6):553-7.
Tufekci S, Coban A, Bor M, Yasa B, Nisli K, Ince Z. Cardiac rhythm abnormalities during intravenous immunoglobulin G(IVIG) infusion in two newborn infants: coincidence or association? Clin Case Rep. 2015;3(9):731-4.
Melhem RA, Mustafa A, Majzoub M, Jalloul Y, Lafferty J, Grovu R, et al. Cardiac sequelae of intravenous immunoglobulin infusion. J Allerg Clin Immunol. 2023;151(2):AB330.
Downloads
Published
How to Cite
Issue
Section
